share_log

Certara Analyst Ratings

Benzinga ·  Oct 11, 2023 08:22
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/11/2023 39.28% Stephens & Co. → $20 Reiterates Overweight → Overweight
08/22/2023 18.38% Jefferies $24.5 → $17 Downgrades Buy → Hold
08/15/2023 67.13% B of A Securities $27 → $24 Maintains Buy
08/11/2023 11.42% Barclays $18 → $16 Maintains Equal-Weight
08/10/2023 1536.49% Morgan Stanley $225 → $235 Maintains Equal-Weight
08/10/2023 William Blair Downgrades Outperform → Market Perform
08/10/2023 46.24% Credit Suisse $27 → $21 Maintains Outperform
07/27/2023 53.2% Morgan Stanley $21 → $22 Maintains Equal-Weight
04/12/2023 94.99% Stephens & Co. → $28 Initiates Coverage On → Overweight
04/04/2023 74.09% Barclays $21 → $25 Downgrades Overweight → Equal-Weight
04/03/2023 74.09% Barclays → $25 Downgrades Overweight → Equal-Weight
03/27/2023 88.02% Credit Suisse $22 → $27 Maintains Outperform
03/10/2023 46.24% Morgan Stanley $20 → $21 Maintains Equal-Weight
03/02/2023 53.2% Credit Suisse $20 → $22 Maintains Outperform
03/02/2023 46.24% Barclays $20 → $21 Maintains Overweight
01/24/2023 39.28% Barclays $17 → $20 Maintains Overweight
12/14/2022 32.31% Baird $17 → $19 Downgrades Outperform → Neutral
11/14/2022 39.28% Credit Suisse $22 → $20 Maintains Outperform
10/06/2022 18.38% Barclays $21 → $17 Maintains Overweight
09/08/2022 60.17% Berenberg → $23 Initiates Coverage On → Buy
08/25/2022 53.2% Credit Suisse → $22 Initiates Coverage On → Outperform
08/24/2022 39.28% Morgan Stanley $24 → $20 Maintains Equal-Weight
08/17/2022 46.24% Barclays $24 → $21 Maintains Overweight
08/10/2022 74.09% Piper Sandler $28 → $25 Maintains Overweight
08/10/2022 81.06% SVB Leerink $29 → $26 Maintains Outperform
07/15/2022 101.95% SVB Leerink → $29 Initiates Coverage On → Outperform
07/13/2022 67.13% Barclays $25 → $24 Maintains Overweight
07/01/2022 94.99% Piper Sandler → $28 Initiates Coverage On → Overweight
05/06/2022 67.13% Morgan Stanley $25 → $24 Maintains Equal-Weight
03/03/2022 74.09% Morgan Stanley $27 → $25 Maintains Equal-Weight
03/03/2022 81.06% Barclays $48 → $26 Maintains Overweight
01/11/2022 115.88% Jefferies → $31 Upgrades Hold → Buy
07/23/2021 108.91% Baird → $30 Initiates Coverage On → Outperform
03/08/2021 129.81% Morgan Stanley $35 → $33 Maintains Equal-Weight
03/03/2021 178.55% Barclays → $40 Initiates Coverage On → Overweight
01/06/2021 143.73% Morgan Stanley → $35 Initiates Coverage On → Equal-Weight
01/05/2021 William Blair Initiates Coverage On → Outperform
01/05/2021 143.73% Credit Suisse → $35 Initiates Coverage On → Neutral
01/05/2021 185.52% B of A Securities → $41 Initiates Coverage On → Buy

What is the target price for Certara (CERT)?

The latest price target for Certara (NASDAQ: CERT) was reported by Stephens & Co. on October 11, 2023. The analyst firm set a price target for $20.00 expecting CERT to rise to within 12 months (a possible 39.28% upside). 18 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Certara (CERT)?

The latest analyst rating for Certara (NASDAQ: CERT) was provided by Stephens & Co., and Certara reiterated their overweight rating.

When is the next analyst rating going to be posted or updated for Certara (CERT)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Certara, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Certara was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.

Is the Analyst Rating Certara (CERT) correct?

While ratings are subjective and will change, the latest Certara (CERT) rating was a reiterated with a price target of $0.00 to $20.00. The current price Certara (CERT) is trading at is $14.36, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment